Here’s what you should know:
1. Mr. Temperato will lead the U.S. commercialization program for the company’s inflammatory bowel disease drug, alicaforsen.
2. He comes to Atlantic after serving as Melinta Therapeutics President and COO. He also had a tenure at Salix Pharmaceuticals.
3. Mr. Temperato said, “I am delighted to join Atlantic Healthcare at what is an extremely exciting time. The highly experienced team has deep roots in pharmaceuticals, alicaforsen enema is in the final stages of clinical trials and a promising pipeline is being developed for alicaforsen tablets in additional GI indications.”
More articles on leadership:
5 takeaways from ACG’s new Crohn’s disease recommendations
5 most-read GI/endoscopy stories: July 26-August 1
Entyvio drives Takeda’s Q1 revenue growth: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.